Quest Diagnostics

CEO Jim Davis, in the role since late 2022, has executed on scale, payer access and advanced diagnostics strategy; 2024 to 2025 actions include LifeLabs closure, multiple outreach deals, new payer collaborations and an Epic partnership to streamline operations. CFO Sam Samad brings seasoned capital allocation and investor communications experience.

Governance has emphasized consistent dividends, cautious leverage and tuck-in M&A. Culture is operationally focused with an increasing tilt toward higher-complexity testing. Execution risk remains in integrating acquisitions and realizing automation benefits, but the team’s cadence on guidance and delivery has been solid.